Gilead boosts immunology pipeline with over $2 billion buyout of Ouro Medicines

2026-04-08 10:52:42

Gilead Sciences announced its acquisition of privately-held biotech firm Ouro Medicines for over $2 billion, aiming to expand its immune disorder drug pipeline. The deal includes an upfront cash payment of $1.68 billion and up to $500 million contingent on milestone achievements. This strategic move provides Gilead access to Ouro’s experimental antibody drug, OM336, currently in early-stage studies for autoimmune conditions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes